A digital therapeutic (DTx) that aims to treat negative symptoms of schizophrenia, like apathy and social withdrawal, has hit the target in a phase 3 trial. The smartphone-based CT-155 app, ...
This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback